#United States #New York #Pomerantz LLP #Rocket Pharmaceuticals #RCKT

Class Action Lawsuit Filed Against Rocket Pharmaceuticals

In a critical development for investors, Pomerantz LLP has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc., a notable player in the biotechnology sector, which trades under the NASDAQ ticker RCKT. This lawsuit is a direct response to allegations of securities fraud and other unlawful practices purportedly conducted by Rocket and certain individuals within its leadership.

Background of the Case

The lawsuit stems from a significant announcement made on May 27, 2025, when Rocket disclosed serious complications regarding its investigational gene therapy for Danon disease, known as RP-A501. The announcement indicated that a participant in the Phase 2 clinical trial had experienced a Serious Adverse Event (SAE) associated with capillary leak syndrome. Following this alarming news, Rocket temporarily halted further dosages in the trial, and just a few days later, the FDA enforced a clinical hold on the study for additional evaluations. Tragically, the patient involved subsequently passed away due to an acute systemic infection.

This series of events led to a dramatic decline in Rocket's stock price, plummeting by $3.94 or 62.84%, resulting in a closing price of $2.33 per share on the same day. Such considerable financial losses have prompted the firm to urge shareholders who were impacted during the class period to come forward and consider joining the lawsuit.

How Investors Can Participate

Investors affected by these developments are prompted to contact Danielle Peyton at Pomerantz LLP. Interested parties can reach out via email or phone, and those opting to email should include pertinent details such as their mailing address, contact number, and the number of shares they acquired during the class period. The deadline to seat as a Lead Plaintiff in this action is August 11, 2025, emphasizing the urgency of this matter for stakeholders.

The firm has made the complaint accessible on its website, where additional information regarding the class action is also provided. Investors are encouraged to review the complaint thoroughly to understand the nature of the allegations and the potential legal repercussions for the company and its officials.

Pomerantz LLP: A Renowned Name in Class Action Litigation

Pomerantz LLP is distinguished as one of the leading firms in corporate, securities, and antitrust class action litigation. Established for over 85 years, the firm carries a legacy of fighting for the rights of investors who have suffered losses due to securities fraud, breaches of fiduciary duties, and various forms of corporate misconduct. Their track record includes remarkable multimillion-dollar settlements for class members, solidifying their reputation in this area of law.

As investors consider their next steps, the litigation landscape surrounding Rocket Pharmaceuticals will undoubtedly unfold further in the coming weeks and months. Stakeholders are advised to remain informed, especially as the August deadline approaches, and to evaluate their options should they wish to participate in the class action. Given the seriousness of the allegations and the significant financial implications, potential participants should act promptly to safeguard their legal rights and interests.

For further information about becoming involved with the class action, please visit Pomerantz Law Firm's website.